Dopamine transporter (DAT) imaging is a key supporting diagnostic examination to distinguish patients with idiopathic parkinsonism (PS) (e.g., Parkinson’s disease, multisystem atrophy, progressive supranuclear palsy, and Lewy body dementia) from patients with Parkinson-like symptoms with preserved dopaminergic function. Here, SLC6A3 is linked to Parkinson disease.